胺碘酮不同给药方法治疗恶性心律失常

目的对胺碘酮不同给药方法治疗恶性心律失常的临床疗效进行观察和探讨。方法选择50例于2012年1月至2013年7月间在我院进行恶性心律失常治疗的患者资料进行研究和分析，将患者分为对照组和治疗组两组，每组各有25例患者，对对照组患者进行胺碘酮治疗，对治疗组患者进行胺碘酮联合门冬氨酸钾镁治疗，比较和分析两组患者的治疗效果。结果对照组8例患者治疗显效，9例患者治疗有效，8例患者治疗无效，治疗总有效率为68％，治疗组15例患者治疗显效，9例患者治疗有效，1例患者治疗无效，治疗总有效率为96％，两组患者治疗效果差异具有统计学意义（P〈0．05）。对照组患者药物起效时间为明显长于治疗组患者，两组患者药物起效时间差异具有统计学意义（P〈0．05）。两组患者不良反应发生情况差异不具有统计学意义（P〉0．05）。结论对恶性心律失常患者进行胺碘酮联合门冬氨酸钾镁治疗能够取得更加理想的治疗效果，值得推广和应用。

Different usages of amiodarone in treatment of malignant arrhythmia

Objective To observe and investigate the clinical efficacy of different usages of amiodarone in the treatment of malignant arrhythmia. Methods The clinical data of 50 patients with malignant arrhythmia treated in our hospital from January 2012 to July 2013 were investigated and analyzed. The patients were divided into control group （n=25） and treatment group （n=25）. The control group was treated with amiodarone, while the treatment group was treated with amiodarone combined with potassium magnesium aspartate. The efficacy was analyzed and compared between the two groups. Results In the control group, 8 cases showed marked response, 9 cases showed response, and 8 cases showed no response, with an overall response rate of 68%, while in the treatment group, 15 cases showed marked response, 9 cases showed response, and 1 case showed no response, with an overall response rate of 96%; there was significant difference in treatment outcome between the two groups （P〈0.05）. The onset time in the control group was significantly longer than that in the treatment group （P〈0.05）. There was no significant difference in incidence of adverse reactions between the two groups （P〉0.05）. Conclusion Amiodarone combined with potassium magnesium aspartate can achieve more ideal efficacy in the treatment of malignant arrhythmia and is worthy of clinical application and promotion.